Stocktoria
REGENERON PHARMACEUTICALS, INC. REGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-04-02
REGENERON PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| R&D expense | $5.9B | $5.1B | $4.4B | $3.6B | $2.9B |
| SG&A expense | $2.7B | $3.0B | $2.6B | $2.1B | $1.8B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B |
| Interest expense | — | — | $73.0M | $59.4M | $57.3M |
| Income tax | $725.8M | $367.3M | $245.7M | $520.4M | $1.3B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B |
| EPS (diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Cash & equivalents | $3.1B | $2.5B | $2.7B | $3.1B | $2.9B |
| Inventory | $3.2B | $3.1B | $2.6B | $2.4B | $2.0B |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B |
| Shareholders' equity | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B |
Source: SEC EDGAR filings · CIK 0000872589 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.